Drug-mediated and cellular immunotherapy in multiple myeloma

Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo

(2014) S. Radhakrishnan et al.   JOURNAL OF IMMUNOLOGY

Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

(2009) Martha Q. Lacy et al.   AMERICAN JOURNAL OF HEMATOLOGY

Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma

(2009) Francis Ayuk et al.   ANNALS OF HEMATOLOGY

Endogenous IL-17 contributes to reduced tumor growth and metastasis

(2009) I. Kryczek et al.   BLOOD

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034): Table 1

(2009) H. Miles Prince et al.   BLOOD

CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT

(2009) M Kapp et al.   BONE MARROW TRANSPLANTATION

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

(2009) Sylvia Feyler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells

(2009) Mónica Bernal et al.   HUMAN IMMUNOLOGY

Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo

(2009) Elisabeth Zinser et al.   IMMUNOBIOLOGY

IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway

(2009) Lin Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection

(2009) M. Basler et al.   JOURNAL OF IMMUNOLOGY

Protumor vs Antitumor Functions of IL-17

(2009) G. Murugaiyan et al.   JOURNAL OF IMMUNOLOGY

Treatment of Myeloma: Cure vs Control

(2009) S. Vincent Rajkumar   MAYO CLINIC PROCEEDINGS

Targeted therapies in multiple myeloma

(2009) Efstathios Kastritis et al.   Targeted Oncology

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study

(2008) Luis F. Porrata et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

(2008) B. Bruno et al.   BLOOD

Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma

(2008) O. C. Goodyear et al.   BLOOD

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

(2008) R. Lapalombella et al.   BLOOD

CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin  IIb 3 in platelets

(2008) S. M. Cifuni et al.   BLOOD

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

(2008) K. M. Dhodapkar et al.   BLOOD

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

(2008) E. Alici et al.   BLOOD

Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade)

(2008) M Arpinati et al.   BONE MARROW TRANSPLANTATION

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody

(2008) Wei Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome

(2008) M. Tinguely et al.   CANCER SCIENCE

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

(2008) T Panaretakis et al.   CELL DEATH AND DIFFERENTIATION

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

NF-??B in the pathogenesis and treatment of multiple myeloma

(2008) Zhi-Wei Li et al.   CURRENT OPINION IN HEMATOLOGY

Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin

(2008) Shiri Moshitzky et al.   IMMUNOLOGY AND CELL BIOLOGY

MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma

(2008) A Curioni-Fontecedro et al.   LEUKEMIA